- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
Stocks are on track to close at fresh records on Friday as the health care sector makes a comeback after a bruising week.
Shares of Biogen soared Friday after the biotech company's early clinical trial data of its experimental Alzheimer's drug was leaked and Eli Lilly's study failed.
Jim Cramer says investors need to be careful speculating on Biogen's treatment for Alzheimer's while investors came away from Broadcom's earnings with a more positive vibe on Apple.
Lilly's sola study did not reduce amyloid plaques in the brain, adding to the likelihood that Biogen's late-stage Alzheimer's study will prove successful.